Luciferase News and Research

RSS
Neutralizing antibody responses against parental SARS-CoV-2 strain as well as against Omicron BA.1 and BA.2 variants

Neutralizing antibody responses against parental SARS-CoV-2 strain as well as against Omicron BA.1 and BA.2 variants

Aminoglycoside antibiotic geneticin shows selective antiviral effect against SARS-CoV-2

Aminoglycoside antibiotic geneticin shows selective antiviral effect against SARS-CoV-2

A new view of SARS-CoV-2 genome structure

A new view of SARS-CoV-2 genome structure

Combating COVID cytokine storm with targeted nucleic acid therapies

Combating COVID cytokine storm with targeted nucleic acid therapies

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Study suggests non-classical inhibition of TBK1/IKKε is protective against severe COVID-19 immunopathology in vivo

Study suggests non-classical inhibition of TBK1/IKKε is protective against severe COVID-19 immunopathology in vivo

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Study shows expression of viral proteases may be used to quantitate SARS-CoV-2 infected cells

Study shows expression of viral proteases may be used to quantitate SARS-CoV-2 infected cells

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

Study compares the neutralizing potential of antibodies against two Omicron variants

Study compares the neutralizing potential of antibodies against two Omicron variants

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

Study shows SARS-CoV-2 prompts NLRP3 inflammasome activation through spike-ACE2 receptor interaction

Study shows SARS-CoV-2 prompts NLRP3 inflammasome activation through spike-ACE2 receptor interaction

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

SARS-CoV-2 shown to spread through cell-to-cell transmission

SARS-CoV-2 shown to spread through cell-to-cell transmission

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Small molecule identified as a SARS-CoV-2 inhibitor

Small molecule identified as a SARS-CoV-2 inhibitor

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.